Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 89 of the 91 references it cites were found in a registry or an index; 51 of the 105 sources its claims cite were checked for support.

Diagnostic Significance of Tryptase for Suspected Mast Cell Disorders

Open access

Abstract

Tryptase has proven to be a very useful and specific marker to demonstrate mast cell activation and degranulation when an acute (i.e., within 4 h after the event) and baseline value (i.e., at least 24 h after the event) are compared and meet the consensus formula (i.e., an increase of 20% + 2). The upper limit of normal determined by the manufacturer is 11.4 ng/mL; however, this boundary has been the subject of debate. According to ECNM and AIM experts, the normal range of baseline tryptase should be 1 to 15 ng/mL. A genetic trait, hereditary alpha tryptasemia, characterized by an increased alpha coding TPSAB1 copy number is associated with a baseline value above 8 ng/mL. Elevated tryptase can also be found in chronic kidney disease, obesity, and hematological neoplasms. A tryptase > 20 ng/mL serves as a minor criterion to diagnose systemic mastocytosis and an increase in tryptase > 20% + 2 during an acute event is a required criterion in the diagnosis of mast cell activation syndrome. The goal of this review is to demonstrate the (in)significance of tryptase using some clinical vignettes and to provide a practical guide on how to manage and interpret an elevated tryptase level.

Overview

CoChat Summary

TL;DR

This narrative review explains how serum tryptase should be interpreted for suspected mast cell disorders, emphasizing paired acute and baseline sampling and the 20% + 2 consensus formula. It uses seven clinical vignettes to show that elevated baseline tryptase is often due to hereditary alpha-tryptasemia or renal failure, while tryptase >20 ng/mL or a documented acute rise supports systemic mastocytosis or MCAS.

Key findings

  • For suspected mast cell activation, acute tryptase should ideally be measured 30–120 min after symptom onset (up to 4 h), paired with baseline tryptase at least 24 h later; the consensus formula is aST ≥ [(1.2 × bST) + 2], i.e., an increase of 20% + 2 ng/mL.
  • Baseline tryptase >20 ng/mL is a minor criterion for systemic mastocytosis, and documented mast cell activation by paired tryptase is a required criterion in mast cell activation syndrome; the manufacturer’s upper limit of normal is 11.4 ng/mL, but ECNM/AIM experts state the normal baseline range should be 1–15 ng/mL.
  • Elevated baseline tryptase is most commonly caused by hereditary alpha-tryptasemia (91%), followed by chronic renal failure (7%) and hematologic malignancies/mastocytosis (1%); hereditary alpha-tryptasemia involves increased alpha-coding TPSAB1 copy number, is associated with baseline tryptase >8 ng/mL, and is found in up to 6% of the general population.
  • In the vignettes, tryptase supported diagnoses such as indolent systemic mastocytosis (aST >200 ng/mL, bST 20 ng/mL), monoclonal MCAS (aST 909 ng/mL, bST 8.3 ng/mL), and hereditary alpha-tryptasemia (bST 19.1 ng/mL with alpha copy number 3 and beta copy number 2).

Methods

  • Narrative review with no primary data collection; it synthesizes literature on tryptase biology, diagnostic criteria, and management of suspected mast cell disorders.
  • Uses seven clinical vignettes (sections 2.1–2.7) of patients with suspected anaphylaxis or mast cell disorders to illustrate interpretation of acute and baseline tryptase.
  • Main analysis is qualitative synthesis; no systematic search, meta-analysis, or formal diagnostic accuracy calculation is reported.

Limitations

  • Stated: the clinical relevance of hereditary alpha-tryptasemia is still under debate because not everyone with the trait experiences mediator-related symptoms or anaphylaxis; the link between hereditary alpha-tryptasemia and systemic mastocytosis remains to be elucidated.
  • Stated: the consensus formula may miss mast cell activation in some patients, especially food-induced anaphylaxis, where only a 30% tryptase increase may suffice; an aST/bST ratio above 1.685 requires further validation, and more research is needed on α/β-tryptase heterotetramers.
  • Evident from the design: this is a narrative review with selected clinical vignettes, not a systematic review or prospective validation study, so the cases are illustrative rather than generalizable.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3390/diagnostics13243662

Cites

89 of 89 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 (A) Proposed algorithm for patients with elevated bST. (B) Proposed algorithm for patients with mediator-related symptoms. MCAS: mast cell activation syndrome; MCA: mast cell activation; CKD: chronic kidney disease; HαT: hereditary alpha tryptasemia; bST: baseline serum tryptase; aST: acute serum tryptase; MIS: mastocytosis in the skin. * Indications for work-up include unexplained osteoporosis or MIS in adults.
Figure 1 (A) Proposed algorithm for patients with elevated bST. (B) Proposed algorithm for patients with mediator-related symptoms. MCAS: mast cell activation syndrome; MCA: mast cell activation; CKD: chronic kidney disease; HαT: hereditary alpha tryptasemia; bST: baseline serum tryptase; aST: acute serum tryptase; MIS: mastocytosis in the skin. * Indications for work-up include unexplained osteoporosis or MIS in adults.CC BY · PubMed Central

Verification

Claims the paper makes

38 Valid · 1 Not valid · 22 Not checked · 29 Own results and interpretations

40 more claims · 11 with their cited sources checked

Create a free account to see all 90 claims and to verify the 1 reference still open.

See all claims — free account
  • Probably not a substantial claim. 22
  • It may state two separate claims as one. 27
  • The quote only partly states this claim. 1

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Show all 91 references

Cited by

See all 22

Metadata

Authors
Beyens, M., Toscano, A., Ebo, D., Gülen, T., & Sabato, V.
Affiliations
  • University of Antwerp (BE)
  • Karolinska University Hospital (SE)
Corresponding author
Ebo, Didier
Venue
Diagnostics
Publisher
MDPI AG
Published
2023-12-14
Volume
13
Issue
24
Pages
3662
ISSN
2075-4418 (ISSN-L)
OpenAlex
W4389737509
Cited by
22
References
91
Citations by year
2026: 11 · 2025: 8 · 2024: 3
FWCI
0.61
Type
journal article
Language
en
Open access
Locations
  • Diagnostics (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Research Foundation Flanders/Fonds Wetenschappelijk Onderzoek (1800614N, 1804518N)
  • Konsul T.H.C. Bergh Foundation, Sweden (1800614N, 1804518N)
  • Swedish Society of Medicine, Sweden (1800614N, 1804518N)
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Mast cells and histamine
  • Health Sciences › Medicine › Rheumatology › Eosinophilic Disorders and Syndromes
  • Health Sciences › Medicine › Immunology and Allergy › Food Allergy and Anaphylaxis Research
Keywords
tryptase, mast cell activation, mast cell degranulation, mast cell disease, systemic mastocytosis, mast cell activation syndrome, hereditary alpha-tryptasemia, TPSAB1, upper limit of normal, chronic kidney disease, obesity, hematologic malignancies, diagnostic criteria

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Diagnostic Significance of Tryptase for Suspected Mast Cell Disorders. https://app.cochat.ai/papers/10.3390/diagnostics13243662
The paper
Beyens, M., Toscano, A., Ebo, D., Gülen, T., & Sabato, V. (2023). Diagnostic Significance of Tryptase for Suspected Mast Cell Disorders. Diagnostics. https://doi.org/10.3390/diagnostics13243662

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.